{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T11:05:25Z","timestamp":1791889525204,"version":"4.3.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T00:00:00Z","timestamp":1604534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T00:00:00Z","timestamp":1604534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Hospital Geral Roberto Santos"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s40256-020-00449-3","type":"journal-article","created":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T20:02:42Z","timestamp":1604520162000},"page":"363-371","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Rivaroxaban Versus Warfarin in Patients with Mechanical Heart Valves: Open-Label, Proof-of-Concept trial\u2014The RIWA study"],"prefix":"10.1007","volume":"21","clinical-trial-number":[{"clinical-trial-number":"nct03566303","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1506-0327","authenticated-orcid":false,"given":"Andre Rodrigues","family":"Duraes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"de Souza Lima Bitar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor Santos","family":"Schonhofen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kethyren Santos Oliveira","family":"Travassos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa Vit\u00f3ria","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Admir\u00e7o Lima","family":"Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansueto Gomes","family":"Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roque Aras","family":"Junior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Roever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,5]]},"reference":[{"key":"449_CR1","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1161\/CIRCULATIONAHA.108.778886","volume":"119","author":"P Pibarot","year":"2009","unstructured":"Pibarot P, Dumesnil JG. Prosthetic heart valves. Circulation. 2009;119:1034\u201348.","journal-title":"Circulation"},{"key":"449_CR2","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/01.CIR.89.2.635","volume":"89","author":"SC Cannegieter","year":"1994","unstructured":"Cannegieter SC, Rosendaal FR, Bri\u00ebt E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation. 1994;89:635\u201341.","journal-title":"Circulation"},{"key":"449_CR3","doi-asserted-by":"crossref","unstructured":"Chiota-McCollum N. From \u201csweet clover disease\u201d to DOACs: A historical perspective on oral anticoagulation for prevention of cardioembolic stroke [Internet]. Neurology. 2016. https:\/\/n.neurology.org\/content\/86\/16_Supplement\/P2.397. Accessed 7 May 2020.","DOI":"10.1212\/WNL.86.16_supplement.P2.397"},{"key":"449_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16528","author":"D Pastori","year":"2020","unstructured":"Pastori D, Lip G, Poli D, Antonucci E, Rubino L, Menichelli D, et al. Determinants of low-quality warfarin anticoagulation in patients with mechanical prosthetic heart valves The nationwide PLECTRUM study [published online ahead of print, 2020 Feb 20]. Br J Haematol. 2020. https:\/\/doi.org\/10.1111\/bjh.16528.","journal-title":"Br J Haematol."},{"key":"449_CR5","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/ejcts\/ezw313","volume":"50","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardio-Thoracic Surg. 2016;50:e1-88.","journal-title":"Eur J Cardio-Thoracic Surg."},{"key":"449_CR6","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/ene.14134","volume":"27","author":"M Costello","year":"2020","unstructured":"Costello M, Murphy R, Judge C, Ruttledge S, Gorey S, Loughlin E, et al. Effect of non-vitamin-K oral anticoagulants on stroke severity compared to warfarin: a meta-analysis of randomized controlled trials. Eur J Neurol Blackwell Publishing Ltd. 2020;27:413\u20138.","journal-title":"Eur J Neurol. Blackwell Publishing Ltd"},{"key":"449_CR7","doi-asserted-by":"crossref","first-page":"e005835","DOI":"10.1161\/JAHA.117.005835","volume":"6","author":"K Pan","year":"2017","unstructured":"Pan K, Singer DE, Ovbiagele B, Wu Y, Ahmed MA, Lee M. Effects of non\u2013vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease: a systematic review and meta-analysis. J Am Heart Assoc. 2017;6:e005835.","journal-title":"J Am Heart Assoc."},{"key":"449_CR8","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","volume":"369","author":"JW Eikelboom","year":"2013","unstructured":"Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369:1206\u201314.","journal-title":"N Engl J Med."},{"key":"449_CR9","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s11239-011-0621-6","volume":"32","author":"A Kaeberich","year":"2011","unstructured":"Kaeberich A, Reindl I, Raaz U, Maegdefessel L, Vogt A, Linde T, et al. Comparison of unfractionated heparin, low-molecular-weight heparin, low-dose and high-dose rivaroxaban in preventing thrombus formation on mechanical heart valves: results of an in vitro study. J Thromb Thrombolysis. 2011;32:417\u201325.","journal-title":"J Thromb Thrombolysis."},{"key":"449_CR10","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/ejcts\/ezt545","volume":"45","author":"LE Greiten","year":"2014","unstructured":"Greiten LE, McKellar SH, Rysavy J, Schaff HV. Effectiveness of rivaroxaban for thromboprophylaxis of prosthetic heart valves in a porcine heterotopic valve model. Eur J Cardio-Thoracic Surg. 2014;45:914\u20139.","journal-title":"Eur J Cardio-Thoracic Surg."},{"key":"449_CR11","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s40268-018-0249-5","volume":"18","author":"AR Dur\u00e3es","year":"2018","unstructured":"Dur\u00e3es AR, de Bitar YSL, Filho JAL, Schonhofen IS, Camara EJN, Roever L, et al. Rivaroxaban versus Warfarin in Patients with Mechanical Heart Valve: Rationale and Design of the RIWA Study. Drugs R D. 2018;18:303\u20138.","journal-title":"Drugs R D."},{"key":"449_CR12","doi-asserted-by":"crossref","first-page":"e1159","DOI":"10.1161\/CIR.0000000000000503","volume":"135","author":"RA Nishimura","year":"2017","unstructured":"Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Fleisher LA, et al. 2017 AHA\/ACC Focused Update of the 2014 AHA\/ACC Guideline for the Management of Patients With Valvular Heart Disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135:e1159\u201395.","journal-title":"Circulation"},{"key":"449_CR13","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1093\/eurheartj\/ehx391","volume":"38","author":"H Baumgartner","year":"2017","unstructured":"Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, et al. 2017 ESC\/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017;38:2739\u201391.","journal-title":"Eur Heart J."},{"key":"449_CR14","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-0038-1651587","volume":"69","author":"FR Rosendaal","year":"1993","unstructured":"Rosendaal FR, Cannegieter SC, van der Meer FJ, Bri\u00ebt E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69:236\u20139.","journal-title":"Thromb Haemost."},{"key":"449_CR15","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1161\/CIRCULATIONAHA.116.026854","volume":"135","author":"JA Reiffel","year":"2017","unstructured":"Reiffel JA. Time in the Therapeutic Range for Patients Taking Warfarin in Clinical Trials. Circulation. 2017;135:1475\u20137.","journal-title":"Circulation"},{"key":"449_CR16","doi-asserted-by":"crossref","unstructured":"Schulman S, Anger SU, Bergqvist D, Eriksson B, Lassen, M. R. &, Fisher W. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost. 2005;8:202\u20134.","DOI":"10.1111\/j.1538-7836.2009.03678.x"},{"key":"449_CR17","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","volume":"123","author":"R Mehran","year":"2011","unstructured":"Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized Bleeding Definitions for Cardiovascular Clinical Trials. Circulation. 2011;123:2736\u201347.","journal-title":"Circulation"},{"key":"449_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-013-0100-7","volume":"53","author":"W Mueck","year":"2014","unstructured":"Mueck W, Stampfuss J, Kubitza D, Becka M. Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban. Clin Pharmacokinet. 2014;53:1\u201316.","journal-title":"Clin Pharmacokinet."},{"key":"449_CR19","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1161\/CIRCRESAHA.119.315099","volume":"126","author":"T Petzold","year":"2020","unstructured":"Petzold T, Thienel M, Dannenberg L, Mourikis P, Helten C, Ayhan A, et al. Rivaroxaban Reduces Arterial Thrombosis by Inhibition of FXa-Driven Platelet Activation via Protease Activated Receptor-1. Circ Res. 2020;126:486\u2013500.","journal-title":"Circ Res."},{"key":"449_CR20","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1161\/ATVBAHA.116.308649","volume":"37","author":"PA Lester","year":"2017","unstructured":"Lester PA, Coleman DM, Diaz JA, Jackson TO, Hawley AE, Mathues AR, et al. Apixaban Versus Warfarin for Mechanical Heart Valve Thromboprophylaxis in a Swine Aortic Heterotopic Valve Model. Arterioscler Thromb Vasc Biol. 2017;37:942\u20138.","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"449_CR21","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/0735-1097(94)00563-6","volume":"25","author":"M Heras","year":"1995","unstructured":"Heras M, Chesebro JH, Fuster V, Penny WJ, Grill DE, Bailey KR, et al. High risk of thromboemboli early after bioprosthetic cardiac valve replacement. J Am Coll Cardiol. 1995;25:1111\u20139.","journal-title":"J Am Coll Cardiol."},{"issue":"6","key":"449_CR22","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.amjcard.2018.06.015","volume":"122","author":"AR Dur\u00e3es","year":"2018","unstructured":"Dur\u00e3es AR, Bitar YDSL, Lima MLG, Santos CC, Schonhofen IS, Filho JAL, et al. Usefulness and safety of rivaroxaban in patients following isolated mitral valve replacement with a mechanical prosthesis. Am J Cardiol. 2018;122(6):1047\u20131050.","journal-title":"Am J Cardiol."},{"key":"449_CR23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.thromres.2019.12.005","volume":"186","author":"E Roost","year":"2020","unstructured":"Roost E, Weber A, Alberio L, Englberger L, Reineke D, Keller D, et al. Rivaroxaban in patients with mechanical heart valves: A pilot study. Thromb Res. 2020;186:1\u20136.","journal-title":"Thromb Res."},{"key":"449_CR24","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/ATVBAHA.117.309223","volume":"37","author":"NC Chan","year":"2017","unstructured":"Chan NC, Weitz JI, Eikelboom JW. Anticoagulation for Mechanical Heart Valves. Arterioscler Thromb Vasc Biol. 2017;37:743\u20135.","journal-title":"Arterioscler Thromb Vasc Biol."}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-020-00449-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-020-00449-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-020-00449-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T19:02:01Z","timestamp":1723834921000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-020-00449-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,5]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["449"],"URL":"https:\/\/doi.org\/10.1007\/s40256-020-00449-3","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,5]]},"assertion":[{"value":"22 October 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by General Hospital Roberto Santos.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors, ARD, YdSLB, ISS, KSOT, LVP, JALF, MGN, RAJ, and LR, declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The trial protocol was approved by the local ethics committee.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided written informed consent before enrollment.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}